Potencjalne kliniczne zastosowanie cząsteczek miRNA w diagnostyce raka prostaty
References
- Aghdam S.G., Ebrazeh M., Hemmatzadeh M., Seyfizadeh N., Shabgah A.G., Azizi G., Ebrahimi N., Babaie F., Mohammadi H.: The role of microRNAs in prostate cancer migration, invasion and metastasis. J. Cell. Physiol., 2019; 234: 9927–9942
- Alford A.V., Brito J.M., Yadav K.K., Yadav S.S., Tewari A.K., Renzulli J.: The use of biomarkers in prostate cancer screening and treatment. Rev. Urol., 2017; 19: 221–234
- Bayraktar R., Van Roosbroeck K., Calin G.A.: Cell-to-cell communication: MicroRNAs as hormones. Mol. Oncol., 2017; 11: 1673–1686
- Boerrigter E., Groen L.N., Van Erp N.P., Verhaegh G.W., Schalken J.A.: Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Rev. Mol. Diagn., 2020; 20: 219–230
- Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., D’Urso L., Pagliuca A., Biffoni M., Labbaye C., Bartucci M., Muto G., Peschle C., De Maria R.: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med., 2008; 14: 1271–1277
- Bonci D., Coppola V., Patrizii M., Addario A., Cannistraci A., Francescangeli F., Pecci R., Muto G., Collura D., Bedini R., Zeuner A., Valtieri M., Sentinelli S., Benassi M.S., Gallucci M. i wsp.: A microRNA code for prostate cancer metastasis. Oncogene, 2016; 35: 1180–1192
- Bucay N., Bhagirath D., Sekhon K., Yang T., Fukuhara S., Majid S., Shahryari V., Tabatabai Z., Greene K.L., Hashimoto Y., Shiina M., Yamamura S., Tanaka Y., Deng G., Dahiya R., Saini S.: A novel micro-RNA regulator of prostate cancer epithelial-mesenchymal transition. Cell Death Differ., 2017; 24: 1263–1274
- Chen D.Q., Yu C., Zhang X.F., Liu Z.F., Wang R., Jiang M., Chen H., Yan F., Tao M., Chen L.B., Zhu H., Feng J.F.: HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9. Ther. Adv. Med. Oncol., 2018; 10: 1758835918783132
- Chen L., Cao H., Feng Y.: MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World J. Urol., 2018; 36: 357–365
- Cochetti G., Rossi de Vermandois J.A., Maulà V., Giulietti M., Cecati M., Del Zingaro M., Cagnani R., Suvieri C., Paladini A., Mearini E.: Role of miRNAs in prostate cancer: Do we really know everything? Urol. Oncol., 2020; 38: 623–635
- Colden M., Dar A.A., Saini S., Dahiya P.V., Shahryari V., Yamamura S., Tanaka Y., Stein G., Dahiya R., Majid S.: MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis., 2018; 8: e2572
- Dong Q., Meng P., Wang T., Qin W., Qin W., Wang F., Yuan J., Chen Z., Yang A., Wang H.: MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One, 2010; 5: e10147
- Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F.: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer., 2019; 144: 1941–1953
- Filella X., Foj L.: miRNAs as novel biomarkers in the management of prostate cancer. Clin. Chem. Lab. Med., 2017; 55: 715–736
- Fu X., Meng Z., Liang W., Tian Y., Wang X., Han W., Lou G., Wang X., Lou F., Yen Y., Yu H., Jove R., Huang W.: miR-26 enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene, 2014; 33: 4296–4306
- Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafrè S.A., Farace M.G.: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem., 2007; 282: 23716–23724
- Goto Y., Kojima S., Nishikawa R., Enokida H., Chiyomaru T., Kinoshita T., Nakagawa M., Naya Y., Ichikawa T., Seki N.: The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget, 2014; 5: 7748–7759
- Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J.: The miR–200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol., 2008; 10: 593–601
- Gu H., Liu M., Ding C., Wang X., Wang R., Wu X., Fan R.: Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1. Cancer Med., 2016; 5: 1174–1182
- Hao P., Kang B., Yao G., Hao W., Ma F.: MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARC. Oncol. Lett., 2018; 15: 4323–4329
- Hsieh I.S., Chang K.C., Tsai Y.T., Ke J.Y., Lu P.J., Lee K.H., Yeh S.D., Hong T.M., Chen Y.L.: MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis, 2013; 34: 530–538
- Hu B., Jin X., Wang J.: MicroRNA-212 targets mitogen-activated protein kinase 1 to inhibit proliferation and invasion of prostate cancer cells. Oncol. Res., 2018; 26: 1093–1102
- Kojima S., Enokida H., Yoshino H., Itesako T., Chiyomaru T., Kinoshita T., Fuse M., Nishikawa R., Goto Y., Naya Y., Nakagawa M., Seki N.: The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J. Hum. Genet., 2014; 59: 78–87
- Lin H.M., Nikolic I., Yang J., Castillo L., Deng N., Chan C.L., Yeung N.K., Dodson E., Elsworth B., Spielman C., Lee B.Y., Boyer Z., Simpson K.L., Daly R.J., Horvath L.G., Swarbrick A.: MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Sci. Rep., 2018; 8: 7820
- Lin P.C., Chiu Y.L., Banerjee S., Park K., Mosquera J.M., Giannopoulou E., Alves P., Tewari A.K., Gerstein M.B., Beltran H., Melnick A.M., Elemento O., Demichelis F., Rubin M.A.: Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res., 2013; 73: 1232–1244
- Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., Wiggins J.F., Bader A.G., Fagin R., Brown D., Tang D.G.: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med., 2011; 17: 211–215
- Liu C., Liu R, Zhang D., Deng Q., Liu B., Chao H.P., Rycaj K., Takata Y., Lin K., Lu Y., Zhong Y., Krolewski J., Shen J., Tang D.G.: MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat. Commun., 2017; 8: 14270
- Liu R.S., Olkhow-Mitsel E., Jeyapala R., Zhao F., Commisso K., Klotz L., Loblaw A., Liu S.K., Vesprini D., Flesher N.E., Bapat B.: Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance. J. Urol., 2018; 199: 1475–1481
- Liu Y.N., Yin J.J., Abou-Kheir W., Hynes P.G., Casey O.M., Fang L., Yi M., Stephens R.M., Seng V., Sheppard-Tillman H., Martin P., Kelly K.: Mir-1 and miR-200 inhibit EMT via slug-dependent and tumorigenesis via slug-independent mechanisms. Oncogene, 2013; 32: 296–306
- Loeb S., Catalona W.J.: The prostate health index: A new test for the detection of prostate cancer. Ther. Adv. Urol., 2014; 6: 74–77
- Lynch S.M., McKenna M.M., Walsh C.P., McKenna D.J.: miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate, 2016; 76: 637–648
- Majid S., Dar A.A., Saini S., Shahryari V., Arora S., Zaman M.S., Chang I., Yamamura S., Tanaka Y., Chiyomaru T., Deng G., Dahiya R.: miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer Res., 2013; 19: 73–84
- Massillo C., Dalton G.N., Farré P.L., De Luca P., De Siervi A.: Implications of microRNA dysregulation in the development of prostate cancer. Reproduction, 2017; 154: R81–R97
- Mihelich B.L., Maranville J.C., Nolley R., Peehl D.M., Nonn L.: Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One, 2015; 10: e0124245
- Miller K.D., Nogueira L., Mariotto A.B., Rowland J.H., Yabroff K.R., Alfano C.A., Jemal A., Kramer J.L., Siegel R.L.: Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin., 2019; 69: 363–385
- Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosowa-Agadjanyan E.L., Peterson A., Noteboom J., O’Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L. i wsp.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA, 2008; 105: 10513–10518
- Ortiz-Quintero B.: Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. Cell Prolif., 2016; 49: 281–303
- Porkka K.P., Pfeiffer M.J., Waltering K.K, Vessella R.L., Tammela T.L., Visakorpi T.: MicroRNA expression profiling in prostate cancer. Cancer Res., 2007; 67: 6130–6135
- Porzycki P., Ciszkowicz E., Semik M., Tyrka M.: Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int. Urol. Nephrol., 2018; 50: 1619–1626
- Rajendiran S., Parwani A.V., Hare R.J., Dasgupta S., Roby R.K., Vishwanatha J.K.: MicroRNA–940 suppresses prostate cancer migration and invasion by regulating MEIN1. Mol. Cancer, 2014; 13: 250
- Rodríguez M., Bajo-Santos C., Hessvik N.P, Lorenz S., Fromm B., Berge V., Sandvig K., Linȇ A., Llorente A.: Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol. Cancer., 2017; 16: 156
- Ru P., Steele R., Newhall P., Phillips N.J., Toth K., Ray R.B.: miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol. Cancer Ther., 2012; 11: 1166–1173
- Selth L.A., Das R., Townley S.L., Coutinho I., Hanson A.R., Centenera M.M., Stylianou N., Sweeney K., Soekmadji C., Jovanovic L., Nelson C.C., Zoubeidi A., Butler L.M., Goodall G.J., Hollier B.G., Gregory P.A., Tilley W.D.: A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 2017; 36: 24–34
- Shi X.B., Xue L., Ma A.H., Tepper C.G., Gandour-Edwards R., Kung H.J., de Vere-White R.W.: Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene, 2013; 32: 4130–4138
- Shi X.H., Li X., Zhang H., He R.Z., Zhao Y., Zhou M., Pan S.T., Zhao C.L., Feng Y.C., Wang M., Guo X.J., Qin R.Y.: A five microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data. Sci. Rep., 2018; 8: 7638
- Stuopelyte K., Daniunaite K., Bakavicius A., Lazutka J.R., Jankevicius F., Jarmalaite S.: The utility of urine-circulating miRNAs for detection of prostate cancer. Br. J. Cancer, 2016; 115: 707–715
- Sun Q., Weng D., Li K., Li S., Bai X., Fang C., Luo D., Wu P., Chen G., Wei J.: MicroRNA-139-5P inhibits human prostate cancer cell proliferation by targeting Notch1. Oncol. Lett., 2018; 16: 793–800
- Tinay I., Tan M., Gui B., Werner L., Kibel A.S., Jia L.: Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. Prostate, 2018; 78: 927–937
- Tokudome S., Ando R., Koda Y.: Discoveries and application of prostate specific antigen, and some proposals to optimize prostate cancer screening. Cancer Manag. Res., 2016; 8: 45–47
- Tomlins S.A., Day J.R., Lonigro R.J., Hovelson D.H., Siddiqui J., Kunju L.P., Dunn R.L., Meyer S., Hodge P., Groskopf J., Wei J.T., Chinnaiyan A.M.: Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur. Urol., 2016; 70: 45–53
- Van Neste L., Hendriks R.J., Dijkstra S., Trooskens G., Cornel E.B., Jannink S.A., de Jong H., Hessels D., Smit F.P., Melchers W.J., Leyten G.H., de Reijke T.M., Vergunst H., Kil P., Knipscheer B.C. i wsp.: Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur. Urol., 2016; 70: 740–748
- Wang M., Yu W., Gao J., Ma W., Frentsch M., Thiel A., Liu M., Rahman N., Qin Z., Li X.: Micro-RNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1. J. Cell Physiol., 2020; 235: 1588–1600
- Wang W., Liu J., Wu Q.: MiR-205 suppresses autophagy and enhances radiosensitivity of prostate cancer cells by targeting TP53INP1. Eur. Rev. Med. Pharmacol. Sci., 2016; 20: 92–100
- Wei J.T., Feng Z., Partin A.W., Brown E., Thompson I., Sokoll L., Chan D.W., Lotan Y., Kibel A.S., Busby J.E., Bidair M., Lin D.W., Taneja S.S., Viterbo R., Joon A.Y. i wsp.: Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J. Clin. Oncol., 2014; 32: 4066–4073
- Williams L.V., Veliceasa D., Vinokour E., Volpert O.V.: miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One, 2013; 8: e83991
- Xu L., Zhong J., Guo B., Zhu Q., Liang H., Wen N., Yun W., Zhang L.: miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1. Tumour Biol., 2016; 37: 12023–12032
- Yang Y., Guo J.X., Shao Z.Q.: miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study. Asian Pac. J. Trop. Med., 2017; 10: 87–91
- Yao J., Xu C., Fang Z., Li Y., Liu H., Wang Y., Xu C., Sun Y.: Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway. Biochem. Biophys. Res. Commun., 2016; 474: 213–219
- Zhang S., Cai J., Xie W., Luo H., Yang F.: miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA. Exp. Ther. Med., 2018; 16: 1499–1504
- Zhou Y.J., Yang H.Q., Xia W., Cui L., Xu R.F., Lu H., Xue Z., Zhang B., Tian Z.N., Cao Y.J., Xing Z.Y., Yin S., He X.Z.: Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2. Life Sci., 2017; 190: 7–14
- Zhu Y., Shao S., Pan H., Cheng Z., Rui X.: MicroRNA-136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen-activated protein kinase 4. Mol. Med. Rep., 2018; 17: 4803–4810
DOI: https://doi.org/10.5604/01.3001.0015.0030 | Journal eISSN: 1732-2693
Language: English
Page range: 491 - 501
Submitted on: Jul 6, 2020
Accepted on: Feb 1, 2021
Published on: Jun 29, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2021 Paweł Porzycki, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.